Gadolinium Deposition Occurs in Early Multiple Sclerosis

Updated August 12, 2019

Research led by Robert Zivadinov, MD, PhD, professor of neurology, found that while a commonly used imaging linear contrast agent, gadodiamide, does accumulate in the brain early in the disease, there is no discernible clinical impact. “This study is one of the first to investigate the longitudinal association between well-established clinical and MRI outcomes of disease severity and gadolinium deposition,” he said. “The findings from this study should be incorporated into a risk-versus-benefit analysis when determining the need for GBCA administration in individual MS patients.”